Latest Rilonacept Stories

TARRYTOWN, N.Y., Jan. 4, 2013 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) has been notified of an unsolicited "mini-tender" offer by TRC Capital Corporation to purchase up to 1 million shares, or approximately 1.06%, of the outstanding Regeneron common stock at a price of $161.25 per share. TRC's offer price represents approximately a 4.46% discount to the closing price of Regeneron common stock on December 27, 2012, the last closing price prior to commencement of...

TARRYTOWN, N.Y., Dec. 20, 2012 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management presentations at the following investor conferences: Goldman Sachs Healthcare CEOs Unscripted: A View from the Top on Thursday, January 3, 2013. The session is scheduled for 3:15 p.m. Eastern Time. 31(st) Annual J. P. Morgan Healthcare Conference on Tuesday, January 8, 2013. The presentation is scheduled for 7:30 a.m. Pacific Time (10:30 a.m. Eastern Time)....

TARRYTOWN, N.Y., Nov. 29, 2012 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it was named "Biotechnology Company of the Year" by Scrip Intelligence at the 8(th) annual Scrip Awards. The Award recognizes the biotech firm that has achieved the most in the 12 months between June 1, 2011 and May 31, 2012. In presenting the award, Scrip said, "Regeneron has been transformed over the past year by the U.S. approval of its first major product. On the...

TARRYTOWN, N.Y., Nov. 27, 2012 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast its presentation at the Deutsche Bank 2012 dbAccess BioFEST on Monday, December 3, 2012. The presentation is scheduled for 1:05 p.m. Eastern Time. The session may be accessed through the Company's web site, www.regeneron.com, on the 'Events and Presentations' page. An archived version of the presentation will be available for 30 days. Regeneron is a fully integrated...

TARRYTOWN, N.Y., Nov. 6, 2012 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management presentations at the following investor conferences: Lazard Capital Markets 9(th) Annual Healthcare Conference at 11:00 a.m. Eastern Time on Tuesday, November 13, 2012 Credit Suisse Healthcare Conference at 9:30 a.m. Eastern Time (7:30 a.m. Mountain Time) on Wednesday, November 14, 2012 Piper Jaffray 24(th) Annual Healthcare Conference at 12:00 p.m. on...

SAN DIEGO, Oct. 26, 2012 /PRNewswire/ -- BioMed Realty Trust, Inc. (NYSE: BMR) today announced that Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) has leased an additional 80,500 square feet of space at The Landmark at Eastview campus in Tarrytown, New York comprised of approximately 46,000 square feet of space in the 777 Building and approximately 34,500 square feet of space in the 765 Building. Named as the world's top biopharmaceutical employer in a recent Science magazine...

TARRYTOWN, N.Y., Oct. 10, 2012 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its third quarter 2012 financial and operating results on Wednesday, October 24, 2012, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM EST that day. Conference Call InformationTo access this call, dial (888) 660-6127 (U.S.) or (973) 890-8355 (International). A link to the webcast may...

TARRYTOWN, N.Y., Sept. 21, 2012 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that EYLEA(®) (aflibercept) Injection has been recommended for approval by the European Committee for Medicinal Products for Human Use (CHMP) for the treatment of patients with neovascular (wet) age-related macular degeneration (wet AMD). The decision of the European Commission on approval is expected in the fourth quarter of 2012. "We are pleased with the positive...

TARRYTOWN, N.Y., Sept. 21, 2012 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced that Science magazine has ranked Regeneron as the #1 employer in the global biopharmaceutical industry in the journal's annual Top Employers Survey. "This recognition by Science as the most respected company to work for in the biopharmaceutical industry is very satisfying for all of us at Regeneron," said Leonard S. Schleifer, M.D., Ph.D., President and Chief Executive...

TARRYTOWN, N.Y., Aug. 29, 2012 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) will webcast management presentations at the following investor conferences: Robert W. Baird Healthcare Conference at 1:20 p.m. Eastern Time on Wednesday, September 5, 2012 Morgan Stanley Global Healthcare Conference at 3:55 p.m. Eastern Time on Tuesday, September 11, 2012 UBS Global Life Sciences Conference at 7:30 a.m. Eastern Time on Thursday, September 20, 2012 The sessions may be...